STSA-1002 is under clinical development by Staidson (Beijing) Biopharmaceuticals and currently in Phase I for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis). According to GlobalData, Phase I drugs for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how STSA-1002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
STSA-1002 overview
STSA-1002 is under development for the treatment of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), antineutrophil cytoplasmic antibody associated vasculitis and acute respiratory distress syndrome. It is a recombinant anti-human C5a IgG1 monoclonal antibody which acts by targeting C5a. It is administered through intravenous and subcutaneous route.
Staidson (Beijing) Biopharmaceuticals overview
Staidson (Beijing) Biopharmaceuticals (Staidson) focuses on the research, development and commercialization of biological protein products. The company’s product portfolio comprises Su peptide Health, an injection of mouse nerve growth factor; Shu Taiqing, Shu Wei Xin, Gliclazide, Nabumetone and aspirin among others. Staidson is headquartered in Beijing, China.
For a complete picture of STSA-1002’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
